Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032708 · ClinicalTrials.gov registry record · Phase 2
Dryvax Dilution-Prev Vacc Adults
A Phase 2 study of Smallpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT00032708 is a Phase 2 study of Smallpox that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants, below the 131,039-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00032708, a Phase 2 study of Smallpox, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
A double-blind, randomized, dose-response study of four dilutions of Dryvax in previously vaccinated adults in order to assess the clinical success rates, humoral responses, and virus-specific actifity of cytotoxi T cells and interferon-y producing T cells
Conditions Studied
Interventions
- BIOLOGICAL Dryvax
Study Locations (1)
Missouri
- Saint Louis University Health Sciences Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032708
The ClinicalTrials.gov registry entry for NCT00032708 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131,039-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smallpox appearing as the primary indexed condition, and to 1 intervention - of which Dryvax is the first listed.
NCT00032708 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00032708 about?
NCT00032708 is a clinical study titled "Dryvax Dilution-Prev Vacc Adults". A double-blind, randomized, dose-response study of four dilutions of Dryvax in previously vaccinated adults in order to assess the clinical success rates, humoral responses, and virus-specific actifity of cytotoxi T cells and interferon-y producing T cells
What is the current status of trial NCT00032708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2004-04. Estimated completion is 2004-11.
What conditions does trial NCT00032708 study?
This clinical trial studies the following conditions: Smallpox.
What interventions are being tested in trial NCT00032708?
The interventions under investigation include: Dryvax (BIOLOGICAL).
Who is sponsoring clinical trial NCT00032708?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032708 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smallpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
ACTIVE NOT RECRUITING · Phase 2
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
COMPLETED · Phase 2
-
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
COMPLETED · Phase 2
-
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
COMPLETED
-
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
COMPLETED
-
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.